SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a

Blood. 2008 Sep 1;112(5):2168; author reply 2169. doi: 10.1182/blood-2008-05-158634.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Alleles
  • Antineoplastic Agents / pharmacology
  • Drug Resistance, Neoplasm / genetics
  • Genes, p53
  • Imidazoles / pharmacology*
  • In Vitro Techniques
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Piperazines / pharmacology*
  • Polymorphism, Single Nucleotide
  • Promoter Regions, Genetic
  • Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-mdm2 / genetics*

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Piperazines
  • nutlin 3
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2